Muhammed Rahaman

With a background in Preclinical Pharmacology, Muhammed obtained his PhD from the University of South Australia. Currently, he is working as a postdoctoral researcher at the Cancer Pharmacogenomics Laboratory at the Centre for Cancer Biology. His research focuses on genomic instability in cancer cells and utilizing this to identify new drug targets for treatment. He previously worked with Professor Shudong Wang in the Drug Discovery and Development group at the University of South Australia. He has extensive experience in the preclinical development of novel anti-cancer targeted agents, particularly cyclin-dependent kinase inhibitors, using both in vitro and in vivo models of cancer. Genomic instability in cancer cells and utilizing this to identify new drug targets for treatment; preclinical development of novel anti-cancer targeted agents, particularly cyclin-dependent kinase inhibitors, using both in vitro and in vivo models of cancer

[2025] Mekonnen, L. B., Teo, T., Noll, B., Rahaman, M. H., Lenjisa, J., Basnet, S., . . . Wang, S. (2025). A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189(118340), 118340. [2025] Safaroghli-azar, A., Mekonnen, L. B., Hassankhani, R., Lenjisa, J., Basnet, S. K. C., Batayneh, H., . . . Wang, S. (2025). A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. Investigational New Drugs, 43(3), 728-741. [2024] Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer, 131(